To investigate the presence of hepatitis B virus (HBV) DNA and hepatitis C virus (HCV) RNA in HIV-infected patients initiating antiretroviral therapy in Cameroon.
Introduction
While HIV-related morbidity and mortality are decreasing thanks to the scaling up of antiretroviral therapy in Africa, co-infections with hepatitis B virus (HBV) or hepatitis C virus (HCV) are catching the attention of medical doctors and other health professionals because of the consequent emerging impact of liver disease [1, 2] . High seroprevalences of all three infections are found in Africa [1] . Unfortunately, the prevalence of active hepatitis B or C co-infections (i.e. positive HBV DNA or HCV RNA) in African patients requiring anti-HIV treatment has not been documented extensively. A recent South African study investigated HBV co-infection (but not HCV co-infection), while a Nigerian study investigated HCV co-infection (but not HBV co-infection) [3, 4] . In contrast, we investigated the presence of both HBV DNA and HCV RNA in HIV-infected patients initiating antiretroviral therapy in Cameroon.
Patients and methods
Patients infected with HIV-1 initiated antiretroviral therapy in 2001-2003 in two major hospitals in Yaoundé in the context of two clinical research projects (109 and 60 patients, respectively) designed to assess antiretroviral treatment. Methods and patients have been described in detail elsewhere [5, 6] . Briefly, the eligibility criteria were: age over 18 years; AIDS or a CD4 count below 350 cells/mL; a Karnofsky score over 50%; and no contraindications to antiretroviral treatment, including serum liver enzyme levels less than five times the upper limit of normal (ULN) value in the first project or less than three times the ULN value in the second project. Hepatitis B and C markers were assessed retrospectively on baseline blood samples frozen at -80 1C. HBsAg result was found to be positive for anti-HBc and had an HBV viral load of 3680 IU/mL. Serology for HCV was positive in 28 patients (16.6%) and indeterminate in four other patients (2.4%). Twentyone patients (12.4% of the total study population, 95% CI 7.9-18.4) were found with HCV RNA (all with positive HCV serology). Therefore, the positive predictive value of HCV serology was 75.0%. The median HCV viral load was 928 000 IU/mL (IQR 178 400-2.06 Â 10 6 ; range 640-5.5 Â 10 6 ). No patient was co-infected with HBV and HCV. Patients co-infected with HBV or HCV were comparable in most characteristics to those infected with HIV alone (Table 1) . However, HCV co-infected patients were more likely to be older and to have serum liver enzyme elevations. HBV co-infected patients had significant serum aspartate aminotransferase (AST) elevations only. In multivariate analysis, HCV co-infection remained associated with greater age [ ! 45 years vs. o45 years, odds ratio (OR) 11.89, 95% CI 3.49-40.55, Po0.001] and abnormal serum alanine aminotransferase (ALT) level ( ! 1.25 Â ULN vs. o1.25 Â ULN, OR 7.81, 95% CI 1.54-39.66, P 5 0.01) but not with abnormal serum AST level ( ! 1.25 Â ULN vs. o1.25 Â ULN, OR 2.65, 95% CI 0.72-9.78, P 5 0.14). After adjustment for gender and serum ALT level, HBV coinfection was associated with abnormal serum AST level only (OR 4.33, 95% CI 1.32-14.17, P 5 0.02).
Discussion
In this study, we found high rates of active HBV and HCV co-infection in HIV-positive patients initiating antiretroviral therapy in Cameroon (8.3 and 12.4%, respectively). Most of these patients had high HBV or HCV viral load and moderate serum liver enzyme elevations.
The true prevalence of co-infections could even be higher because seronegative blood samples were not tested for HBV DNA or HCV RNA. Higher rates of negative HBsAg or anti-HCV EIA results in viraemic samples have been observed in immunocompromised HIV-infected patients [2, 7] . In addition, the exclusion of patients presenting with serum liver enzyme levels higher than three or five times the ULN values (depending on the initial study) could have led to an underestimation of the prevalence. The comparison of our HBV and HCV estimates to those reported by the few other African studies in patients initiating antiretroviral therapy should be viewed as indicative only because of the methodological differences. In South Africa, HBV DNA was detected in 40.6% of 192 patients (100% of 44 HBsAg-positive patients and 23.0% of 148 HBsAg-negative patients) [3] . In Cameroon's neighbour Nigeria, 8.2% of 146 patients were found with HCV RNA (all patients were tested for HCV viraemia) [4] . The prevalence of co-infections in other HIV-infected populations are much lower. For instance, HBV DNA was detected in 2.4% of pregnant women in both Côte d'Ivoire and South Africa [8, 9] . The prevalence of HCV RNA was 0% in blood donors in Tanzania and 1.0% in pregnant women in Côte d'Ivoire [8, 10] . Frequent co-infections are also found in Europe and the USA, where the prevalence of HIV, HBV and HCV in the general population is lower than in Africa. However, the predominant modes of transmission of all three infections are similar in Western countries (intravenous drug use and sexual contact) [11, 12] whereas they appear very dissimilar in Africa (for HIV, the heterosexual route; for HBV, close contact within households during early childhood and, to a lesser extent, vertical transmission; and for HCV, unclear routes of transmission) [1, 2] .
Undetected HBV or HCV co-infections had clinical implications for antiretroviral therapy in our patients. All HBV co-infected patients received anti-HBV lamivudine monotherapy, which has been shown to lead to frequent emergence of drug resistance [13] and, consequently, to possible acute hepatitis, fulminant hepatic failure and death [2] . The World Health Organization now recommends the use of tenofovir plus either lamivudine or emtricitabine as the nucleoside reverse transcriptase inhibitor (NRTI) backbone of antiretroviral therapy in HBV co-infected patients whenever possible (tenofovir has been available in Cameroon since 2007) [14] . Also, 46 and 55% of HBV and HCV co-infected patients, respectively, received nevirapine despite moderate liver enzyme elevations. In these patients, efavirenz or a third NRTI is preferred [14] .
Two strategies should be considered for the management of HIV-infected patients needing treatment in Africa. Where possible, testing for HBsAg and anti-HCV should be performed systematically in addition to serum liver enzymes before initiating antiretroviral therapy in order to avoid nevirapine and anti-HBV lamivudine monotherapy when necessary. Moreover, where possible (infrequent at present in most African settings), HBV DNA and HCV RNA should also be tested when hepatic infection is suspected in order to identify patients with occult hepatitis B (negative HBsAg and positive HBV DNA) or false negative anti-HCV EIA results. Testing for HBV DNA would also limit the inessential use of the costly tenofovir (23.5% of our HBsAg-positive patients were not viraemic). If quantitative assay can be performed, HBV DNA level (or HCV RNA level if anti-HCV treatment is available) would serve to manage antiviral therapy (initiation and response). Alternatively, if testing of HBV and HCV is not feasible, first-line antiretroviral regimen in HBV-endemic African countries should include tenofovir plus either lamivudine or emtricitabine systematically. The combination of tenofovir, emtricitabine and efavirenz, once a day, appears a very good option. If nevirapine is prescribed, serum liver enzymes should be monitored closely.
In conclusion, active HBV and HCV co-infections were frequent in HIV-positive Cameroonian patients requiring antiretroviral therapy. This finding underlines the need to promote: (i) screening for HBV and HCV before treatment initiation; (ii) accessibility to tenofovir (especially in HBVendemic African countries); and (iii) accessibility to treatment for HBV and HCV infections (in addition to NRTIs).
